Jasper Therapeutics, Inc. (JSPR)
D
Pipeline Grade
Financial Position (from SEC Filings)
$14.6M
Cash & Equivalents
$14.6M
Quarterly Burn Rate
3 mo
Est. Cash Runway
$16M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-08-13 | Phase2 Readout | — |
| 2026-10-31 | Phase2 Readout | — |
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06736262 | A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants... | PHASE2 | Active Not Recruiting | 67 |
| NCT06162728 | Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adu... | PHASE2 | Active Not Recruiting | 88 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.